Daan Gene
Daan Gene is an in-vitro diagnostics company supplying disease-diagnosis products and planning labs running clinical analyses for hospitals and individuals.
- Acquired Subsidiary
- Guangzhou, GD, CNChina
Daan Gene is an in-vitro diagnostics company supplying disease-diagnosis products and planning labs running clinical analyses for hospitals and individuals.
daangene.comCrawled Nov 7, 2026
Daan Gene Co., Ltd. develops diagnostic test kits, automatic extractors, and real-time PCR systems, along with core raw materials, CRMs, and clinical analysis labs for hospitals and individuals.
Guangzhou Daan Gene Co., Ltd. is a state-owned biotech company specializing in molecular diagnostics, developing and selling clinical testing reagents and instruments, and operating a chain of independent medical labs for clinical testing services.
Daan Gene Co., Ltd. reports **CNY 522.28 million in sales and revenue** for the nine months ending September 30, 2026, marking a year-over-year increase from CNY 503.51 million. The company’s financial results reflect growth in its core operations over the period. Figures highlight a sequential improvement in financial performance.
Oct 2026MarketScreenerNews article
Guangzhou Pharmaceutical Group secures a 26.63% controlling stake in Da An Gene, an in-vitro diagnostics (IVD) company. The acquisition, completed over a month prior, integrates Da An Gene into GP Pharma Capital’s portfolio. Despite the deal, Da An Gene reports a first-half loss of 120 million yuan.
Oct 2026BigGo FinanceNews article
Chinese pharmaceutical stocks surge on October 8 as Da An Gene, North China Pharmaceutical, Rundu Pharmaceutical, and Vland Biotech hit the 10% daily trading limit amid rumors of plague outbreaks. ZBD Pharmaceutical also rises over 7% before prices retreat in later trading. The volatility follows China’s National Day holiday and coincides with flu data reports.
Oct 2026BigGo FinanceNews article
GPC Capital, a subsidiary of Guangzhou Pharmaceutical Holdings, acquires a **26.63% stake in Daan Gene** for **2.42 billion yuan** ($355.5 million) in cash. The deal, announced on May 18, marks a strategic investment by Guangzhou’s state-owned capital system to bolster the diagnostics leader amid reported financial losses. Daan Gene operates in the medical diagnostics sector, and the acquisition may signal efforts to stabilize its operations.
May 2026BigGo FinanceNews article